Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Budoprutug · TNT119, VB-119

Monoclonal antibody · Acts on CD19 · developed by Climb Bio

Phase 1/2 Most advanced trial

CLYM Developer

1 Registered trials

What is Budoprutug?

Budoprutug (also known as TNT119 and VB-119) is a monoclonal antibody directed against CD19, a B-cell surface protein. It is being studied in immune thrombocytopenia (ITP), given as a single intravenous dose on Day 1 and Day 15.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TNT119, VB-119
Drug type: Monoclonal antibody
Targets: CD19
Mechanism: Acts on CD19
Therapy area: Hematology
Developer: Climb Bio, Inc. (CLYM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: E4ET672BAP

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07043946	Phase 1/2	Immune Thrombocytopenia (ITP)	Recruiting	CLYM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anti-CD19BiologicsImmune Thrombocytopenia (ITP)ITPMonoclonal

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved MK-1045 Phase 2/3

More from Climb Bio

CLYM116 Phase 1

Sources

ClinicalTrials.gov NCT07043946

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLYM page.

Follow CLYM, the company behind Budoprutug

See CLYM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLYM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z